Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Craig W. Hendrix, M.D.
Craig Walter Hendrix, M.D.
Wellcome Professor and Director, Division of Clinical Pharmacology
Professor of Medicine
Research Interests: Chemoprevention of HIV infection; Drug interactions; Clinical pharmacology of antiviral drugs; Topical HIV microbicides
Contact for Research Inquiries
600 N. Wolfe Street
Baltimore, MD 21287 map
Dr. Hendrix is a Professor of Medicine and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He has 25 years of experience in the design and conduct of translational clinical pharmacology studies, mostly of antiretroviral drugs for HIV treatment and prevention. He is the Wellcome Professor and Director, Division of Clinical Pharmacology and Director of the Drug Development Unit in the Division. His research focuses on development of antiretroviral drugs to prevent HIV infection. His HIV prevention research has been supported by CDC, NIH, USAID, the Bill and Melinda Gates Foundation, amfAR, and sponsors in the pharmaceutical industry.
Dr. Hendrix received his undergraduate degree in Applied Biology at MIT (1978) and his medical degree from Georgetown University, magna cum laude (1984). He completed internship and residency in internal medicine on the Osler Medical Service, and fellowships in Infectious Diseases and Clinical Pharmacology at The Johns Hopkins Hospital. Before joining the Hopkins medical school faculty, Dr. Hendrix served on active duty for 10 years in the U.S. Air Force (USAF) where he was Director of the Air Force HIV Research and Education Program while assigned to Wilford Hall USAF Medical Center in San Antonio, TX (1989-2004), and he developed HIV prevention education programs for the United States military, United Nations Department of Peacekeeping Operations, and other militaries worldwide while assigned to the Division of Retrovirology, Walter Reed Army Institute of Research (1994-1996) and attached to the USAF Surgeon General's Office (USAF Reserve, 1997-1999).
Dr. Hendrix was appointed as the Wellcome Professor and Director, Divsiion of Clinical Pharmacology 1 January 2015. Established in 1954, the Division of Clinical Pharmacology at The Johns Hopkins University School of Medicine is one of the oldest in the world, and has a long history of laboratory and clinical research, teaching, and service activities. The Division of Clinical Pharmacology at the Johns Hopkins University School of Medicine is part of both the Departments of Medicine and the Department of Pharmacology and Molecular Sciences. Research efforts of the current faculty focus primarily on therapies for infectious diseases: antibiotics, antiparasitics, antifungals, and antivirals. Of particular interest are studies that translate laboratory discoveries into clinical practice. The Clinical Pharmacology faculty at Johns Hopkins teach undergraduates, all four years of medical students, graduate students in three Schools of the University, housestaff, and peer physicians. The Division also impacts directly on patient care at the Johns Hopkins Hospital via the office of the Hospital Pharmacologist and through several faculty who serve as Osler firm faculty.
Currently, Dr. Hendrix also serves as Director of the Drug Development Unit (DDU) which focuses on early phases of clinical drug development. The DDU is a core facility that provides support to Hopkins faculty to design, execute, and analyze clinical protocols across many therapeutic areas. DDU specializes in first in human, phase I pharmacokinetic, and phase II proof of concept studies. Dr. Hendrix's primary research focus the past decade has been chemoprevention of HIV infection which includes developing topical microbicides to prevent sexual transmission of HIV. The DDU has supported Dr. Hendrix's own research by performing key studies to understand distribution of HIV after sexual exposure, distribution of drugs within the female genital tract and colon, and the impact of microbicide vehicles on mucosal health and resistance to HIV infection.
Through the support services of the Clinical Pharmacology Analytical Laboratory (CPAL), also in the Division of Clinical Pharmacology, Dr. Hendrix has been actively involved in randomized controlled trials of drugs for pre-exposure prophylaxis (PrEP) of HIV. CPAL's work is integral to the Pharmacology Core function of the NIH-funded HIV Prevention Trials Network (HPTN) and the Microbicide Trials Network (MTN) and contributed directly to the FDA's licensure of Truvada® for prevention of HIV infection. For both the HPTN and MTN, Dr. Hendrix serves as Director of the Pharmacology Core Laboratory.
Mentoring and teaching medical students, graduate students, and post-doctoral fellows have long been his passion and integral to the success of his own research accomplishments. Dr. Hendrix is a recipient of the Johns Hopkins Alumni Association Excellence in Teaching Award and the David M. Levine Faculty Mentoring Award at Hopkins. Seen as an opportunity to inform faculty colleagues, he has served on the Hopkins institutional review board for the past 16 years.
Dr. Hendrix has served on the FDA Antiviral Drug Products Advisory Committee, the Board of Scientific Counselors for the National Center for Infectious Diseases, and the Board of the American Society of Clinical Pharmacology and Therapeutics.
- Wellcome Professor and Director, Division of Clinical Pharmacology
- Director, Drug Development Unit
- Deputy Director, Translational Science Core, Institute for Clinical and Translational Research (CTSA)
- Professor of Medicine
- Professor of Pharmacology and Molecular Sciences
- American Board of Internal Medicine (1987)
- American Board if Internal Medicine - Infectious Diseases (1990)
The Johns Hopkins Hospital Osler Medical Service, Baltimore, MD, 1987, Internal Medicine Residency; Johns Hopkins University School of Medicine, Baltimore, MD, 1989, Infectious Diseases, Clinical Pharmacology
Research & Publications
Dr. Hendrix's primary research focus is chemoprevention of HIV infection. This involves oral, topical, and injectible HIV microbicide development. He conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract. He also supports numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV PRevnetion Trials Network.
Lab Website: Clinical Laboratory and Biomarkers Core
Selected PublicationsView all on Pubmed
Selected from over 140 Original Scientific Papers
- Mayer KH, Maslankowski L, Gai F, El-Sadr W, Justman J, Kwiecien A, Masse B, Eshleman S, Hendrix CW, Morrow K, Absalon J, Rooney J, Soto-Torres L. Tenofovir vaginal gel: Safety and tolerability in low-risk HIV-uninfected women and HIV-infected women (HPTN 050). AIDS 2006;20(4):543-551.
- Ndovi TT, Choi L, Caffo B, Parsons T, Baker S, Zhao M, Rohde C, Hendrix CW. Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a non-invasive method. Clin Pharmacol Ther 2006;80(2):146-158.
- Ndovi TT, Parsons T, ChoiL, Caffo B, Rohde C, HendrixCW. A New Method to Quantitatively Estimate Seminal Vesicle and Prostate Gland Contributions to Ejaculate. Br J Clin Pharmacol 2007;63(4):404-20.Epub 2006 Oct 31.
- Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, Wahl RL, Hendrix CW. Hyperosmolar Sexual Lubricant Causes Epithelial Damage in the Distal Colon: Potential Implication for HIV Transmission. J Infect Dis 2007;195(5):703-710.Epub 2007 Jan 23.
- Ndovi TT, Cao YJ, Fuchs EJ, Fletcher CV, Guidos A, Hendrix CW. Food affects zidovudine concentration independent of effects on gastrointestinal absorption. J Clin Pharmacol 2007;47(11):1366-73.
- Hendrix CW, FuchsEJ, Macura KJ, Lee LA, Parsons TL, Bakshi RP, Khan WA, Guidos A, Leal JP, Wahl R. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther 2008 Jan;83(1):97-105. Epub 2007 May 16.
- Choi L, Caffo BS, Rohde C, Ndovi TT, Hendrix CW. A Mechanistic Latent Variable Model for Estimating Drug Concentrations in the Male Genital Tract: A Case Study in Drug Kinetics. Stat Med 2008 Jun 30;27(14):2697-714.
- CaoYJ, NdoviTT, ParsonsTL, Guidos A, CaffoB, HendrixCW. Effect of semen sampling frequency on seminal antiretroviral drug concentration. Clin Pharmacol Ther. 2008 Jun;83(6):848-56.
- Cao Y-J, Hendrix CW. Male Genital Tract Pharmacology: Developments in Quantitative Methods to Better Understand a Complex Peripheral Compartment. Clin Pharmacol Ther . 2008 Mar;83(3):401-12.
- Cao YJ, Caffo B, Choi L, Radebaugh C, Fuchs EJ, Hendrix CW. Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. J Clin Pharmacol. 2008 Feb;48(2):176-83. Epub 2007 Dec 19.
- Caffo B, Crainiceanu C, Deng L, Hendrix CW. A Case Study in Pharmacologic Imaging Using Principal Curves in Single Photon Emission Computed Tomography. J American Statistical Assoc 2008, 103(484):1470-1480. PMC2794148
- Nyunt M, Hendrix CW, Bakshi R, Kumar N, Shapiro TA. Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with plasmodium falciparum sporozoites. Am J Trop Med Hyg 2009;80(4):528-35.
- Goldsmith J, Caffo B, Crainiceanu C, Reich D, Chen Y, Hendrix CW. Non-linear Tube Fitting for the Analysis of Anatomical and Functional Structures. Ann Appl Stat. 2011 Jan 1;5(1):337-363. PMC3119905
- Avery LB, Bakshi RP, Cao YJ, Hendrix CW. The male genital tract is not a pharmacological sanctuary from efavirenz. Clin Pharm Ther 2011 Jul;90(1):151-6. PMC3215581
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. Epub 2011 Jul 18. PMC3200068
- Dezzutti CS, Hendrix CW, Marrazzo J, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC Comparing Swabs, Lavage, and Diluents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators. 2011 PloS One 2011;6(8):e23136. PMC3155537
- Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, Hendrix CW, Mâsse B, Valentine M, Piper J, Watts DH. Pharmacokinetics and Placental Transfer of Single Dose Tenofovir 1% Vaginal Gel in Term Pregnancy. J Infect Dis 2011 2011 Nov;204(10):1527-31. PMC3192189
- Wang L, Schnaare RL, Dezzutti C, Hendrix CW, Anton PA, Rohan LC. Rectal microbicides: Clinically relevant approach to the design of rectal specific placebo formulations. AIDS Research Therapy, 8:12, 2011. PMC3061893
- Louissaint NA, Nimmagadda S, Fuchs EJ, Bakshi RP, Cao Y, Lee L, Goldsmith AJ, Caffo B, Du Y, King KE, Menendez FA, Torbenson MS, Hendrix CW. Distribution of Cell-free and Cell-associated HIV surrogates in the Colon Following Simulated Receptive Anal Intercourse in Men. J Acquir Immune Defic Syndr 2012 Jan 1;59(1):10-17. PMC3237874
- Louissaint NA, Fuchs EJ, Bakshi RP, Nimmagadda S, Du Y, Macura K, King KE, Goldsmith AJ, Caffo B, Cao Y, Anderson JR, Hendrix CW. Distribution of Cell-free and Cell-associated HIV Surrogates in the Female Genital Tract following Simulated Vaginal Intercourse. J Infect Dis 2012 Mar;205(5):725-32. NIHMS331989
- Lu Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L, Hendrix CW. Acyclovir achieves lower concentration in African HIV-seronegative, HSV-2 seropositive women compared to non-African populations. Antimicrob Agents Chemother 2012 May;56(5): 2777-2779. PMC 3346629
- Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Jordan W. Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A , Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix CW, Bumpus N, Bangsberg D, Haberer J, Stevens WS, Lingappa JR, Celum C. Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women. N Engl J Med 2012 Aug 2;367(5):399-410.
- Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Segolodi TM, Soud FA, Henderson FL, Pathak SR, Rose CE, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde K, Abebe D. Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT. Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana: the TDF2 Study. N Engl J Med 2012 Aug 2;367(5):423-34.
- Cao YJ, Caffo BS, Fuchs EJ, Lee LA, Du Y, Li L, Bakshi RP, Macura K, Khan WA, Wahl RL, Grohskopf LA, Hendrix CW. Quantification of the Spatial Distribution of Rectally Applied Surrogates for Microbicide and Semen in Colon with SPECT Imaging. Br J Clin Pharmacol 2012 Dec;74(6):1013-22 PMC3522815
- Lu, Y, Hendrix CW, Bumpus NN. Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-HIV Drug Maraviroc. Drug Metabol Disp 2012 Dec;40(12):2221-30. doi: 10.1124/dmd.112.048298. Epub 2012 Aug 24. PMC3500548
- Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Diéguez A, Mauck C, McGowan I. RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Compared to Oral Tenofovir DF. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21. doi: 10.1089/AID.2012.0262. Epub 2012 Oct 9. PMC3484811
- Minnis AM, Gandham S, Richardson BA, Guddera V, Riddler S, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW. Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav 2012 Feb;17(2):737-47. PMC3562423
- Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN. Compartmentalization and Antiviral Effect of Efavirenz Metabolites in Blood Plasma, Seminal Plasma and Cerebrospinal Fluid. Drug Metabo Disp 2012 Nov 19. [Epub ahead of print] PMCID: PMC3558859
- Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus N. Pharmacokinetic cross-over study in women comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other anatomic compartments (MTN-001) PLoS One. 2013;8(1):e55013. PMC3559346
- Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW. Quantitative Assessment of Altered Rectal Mucosal Permeability Due to Rectally Applied Nonoxynol-9, Biopsy, and Simulated Intercourse. J Infect Dis 2013 May 1;207(9):1389-96 PMC3693591
- Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free Efavirenz is Equivalent in Cerebrospinal Fluid & Blood Plasma: Applying the Law of Mass Action to Predict Protein-Free Drug Concentration. Antimicrob Agents Chemother 2013 Jan:57(3):1409-1414. Jan 7[Epub ahead of print]. PMCID: PMC3591913
- Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW. Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic and Vaginal Tissue. AIDS Res Hum Retroviruses 2013 Nov: 29(11): 1443-1450. PMC3809387
- Avery LB, Zarr M, Bakshi RP, Siliciano R, Hendrix CW. Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. AIDS Res Hum Retroviruses 2013 Nov;29(11): 1434-1442. PMC3809607
- Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze R, McNicholl J, Paxton L, Curlin M, Hendrix CW, Vanichseni S, for the Bangkok Tenofovir Study Group. Antiretroviral Prophylaxis for HIV Infection among People Who Inject Drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial. Lancet 2013 Jun 15;381(9883):2083-90.
- Leyva FJ, Bakshi R, Fuchs EJ, Li L, Caffo BS, Goldsmith AJ, Carballo-Dieguez A, Ventuneac A Du Y, Leal J, Lee LA, Torbenson MT, Hendrix CW. Iso-osmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyper- and hypo-osmolar enemas as a potential delivery vehicle for rectal microbicides. AIDS Res Hum Retroviruses 2013 Nov:29(11): 1487-1495. PMC3809953
- To E, Hendrix CW, Bumpus NN. Dissimilarities in the Metabolism of Antiretroviral Drugs used in HIV Pre-exposure Prophylaxis in Colon and Vagina Tissues. Biochem Pharmacol 2013 Oct 1;86(7):979-90. PMC3807636.
- Chaturvedula A, Fossler M, Hendrix CW. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. J Clin Pharmacol 2013 Nov 6; 54(2): 150-60. PMCID in process
- Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW. Antiviral Activity of Genital Tract Secretions following Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1. J Acquir Immune Defic Syndr. 2014 May 1; 66(1):65-73. PMC3981887
- Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Gvetadze RJ, Kittimunkong S, Curlin ME, Worrajittanon D, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group. Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs. PLoS One. 2014 Mar 25;9(3):e92809. PMC3965466
- Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer JE, Mujugira A, Hendrix CW, Celum C. HIV Protective Efficacy and correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. J Acquir Immune Defic Syndr. 2014 Apr 29 [Epub ahead of print]. PMC4059553
- Lu Y., Fuchs EJ, Hendrix CW, Bumpus NN. Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers. Drug Metabol Disp 2014 Aug 12. pii: dmd.114.060194. [Epub ahead of print] PMCID in progress.
- Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix CW, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team. Single-Agent Tenofovir versus Combination Emtricitabine/Tenofovir for Pre-Exposure Prophylaxis against HIV-1 Acquisition: A Randomized Trial. Lancet Infectious Diseases 2014 Oct 6. pii: S1473-3099(14)70937-5.
- Yang K, Hendrix CW, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD. A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. PLoS One. 2014 Oct 28;9(10):e106196.
- Richardson-Harman N, Hendrix CW, Bumpus NN, Mauck C, Cranston RD, Yang K, Elliott J, Tanner K, McGowan I, Kashuba ADM, Anton PA. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 Phase 1 study. PLoS One. 2014 Oct 28;9(10):e111507.
- Madrasi K, Burns R, Hendrix CW, Fossler M, Chaturvedula A. Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT: Pharmacometrics & Systems Pharmacology 2014 Nov 12;3:e147.
- Burns RN, Hendrix CW, Fossler MJ, Chaturvedula A. Population Pharmacokinetics of Tenofovir and Tenofovir-diphosphate in healthy women. J Clin Pharmacol 2015 Jan 8. doi: 10.1002/jcph.461. [Epub ahead of print]
- Marrazzo JM, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G, Palanee T, Nakabito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, ParikhU, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke M, Hillier SL, McGowan IM, Chirenje ZM, VOICE Study Team. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 2015 Feb. 2.
Academic Affiliations & Courses
Graduate Program Affiliation
Clinical Pharmacology Training Program
Graduate Training Program in Clinical Investigation
Research Training in Microbial Diseases
Activities & Honors
- David M. Levine Faculty Mentoring Award, Department of Medicine
- Excellence in Teaching Award, Johns Hopkins Alumni Association
- American Society of Clinical Pharmacology and Therapeutics
- American Society for Clinical Pharmacology and Therapeutics